



**Biocon Limited**

20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

May 1, 2022

To, The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To, The Manager <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol – Biocon</b>
--	---

**Subject: Newspaper Advertisement- Financial Results Quarter and Financial Year ended March 31, 2022**

Dear Sir/Madam,

In continuation to our letter dated April 28, 2022 with regards to Financial Results for the quarter and year ended March 31, 2022, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on April 30, 2022.

The above information is also available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

*Mayank Verma*



**Mayank Verma**  
**Company Secretary & Compliance Officer**

**Enclosed:** Copies of Newspaper advertisements



## FINANCIAL EXPRESS

**OFFICE OF THE CHIEF ENGINEER(WW) THROUGH EE (E&M) HP-1  
DELHI JAL BOARD: GOVT. OF NCT OF DELHI  
HAIDER PUR WATER WORKS, DELHI - 110085  
Tel No. 011-2755246-47, Email ID: eemhp1.djb@nic.in**

**Press N.I.T. NO.1 (2022-23)**

No.	Name of work	Approximate value based on Schedule of rates/ Item rates/ lump sum (Rs in lacs)	Earnest Money in Rs.	Tender Fee	Date of release of tender in e-procurement solution	Last date/time of receipt of tender through e-procurement solution
1.	Renting out of existing DJB Sites for installations of Mobile Network Towers 98 Nos at Various WPT/STP/BPS/SPS and tube wells space of DJB. Tender ID: 2022_DJB_22124_1	Item Rate	Rs. 454 Lacs/-	1500/-	28.04.2022	19.05.2022

Further details in this regard can be seen at <https://delhi.govtprocurement.com>.

ISSUED BY P.R.O. (WATERS)  
Adv. No. J.S.V. 70 (2022-23)

Sd/-  
(SUNIL KUMAR)  
EE (E&M) HP-1

STOP CORONA; WEAR MASK; MAINTAIN SOCIAL DISTANCING AND MAINTAIN HAND HYGIENE

## CANARA ROBECO

## Canara Robeco Mutual Fund

Investment Manager : Canara Robeco Asset Management Co. Ltd.  
Construction House, 4th Floor, 5, Walchand Hirachand Marg, Ballard Estate, Mumbai 400 001.  
Tel.: 6658 5000 Fax: 6658 5012/13 www.canararobeco.com CIN No.: U65990MH1993PLC071003

## NOTICE CUM ADDENDUM NO. 07

## Change in the constitution of the Board of Trustees of Canara Robeco Mutual Fund:

All unit holders of Canara Robeco Mutual Fund are requested to take note of the following change in the constitution of the Board of Trustees of Canara Robeco Mutual Fund:

Mr. Sanjay Arya has been appointed as an Independent Trustee on the Board of Trustees of Canara Robeco Mutual Fund with effect from 25<sup>th</sup> April, 2022. His details are given as under:

Name	Age/Qualification	Brief Experience
Mr. Sanjay Arya	65 Years/ BSc, MA (Economics), CAIIB, Diploma in Management, PG Diploma in Treasury & Risk Management and Financial Advising.	Mr. Sanjay Arya is a career banker having worked 39 years with Bank of Maharashtra and thereafter with United Bank of India. He started his career as Probationary Officer with Bank of Maharashtra and rose to the position of General Manager of the Bank. During his tenure with the Bank, he has worked in various capacities including Head of various departments and has a rich and cross functional banking experience in Financial Management & Corporate Accounts, Integrated Treasury functions, Retail Lending, heading the Priority Sector department, Corporate and Industrial Finance and related functions. Thereafter, he was associated with United Bank of India as Executive Director till superannuation in 2016.

This addendum shall form an integral part of the Statement of Additional Information for the schemes of Canara Robeco Mutual Fund as amended from time to time.

## NOTICE-CUM-ADDENDUM NO. 08

## Disclosure of Half Yearly Unaudited Financial Results of Schemes of Canara Robeco Mutual Fund:

All unit holders of Canara Robeco Mutual Fund are requested to note that in terms of Regulation 59 of SEBI (Mutual Funds) Regulations, 1996 and SEBI circulars issued in this regard from time to time, the Half Yearly Unaudited Financial Results of the Schemes of Canara Robeco Mutual Fund for the period ended March 31, 2022 have been hosted on the website of Canara Robeco Mutual Fund, [www.canararobeco.com](http://www.canararobeco.com).

The unit holders can visit the following link for viewing/downloading the aforesaid results:

<https://www.canararobeco.com/statutory-disclosures/un-audited-half-yearly-financial-results>

Unit holders are requested to visit [www.canararobeco.com](http://www.canararobeco.com) to claim their Unclaimed Redemption & Dividend amounts and follow the procedure prescribed therein.

For and on behalf of Canara Robeco Asset Management Company Ltd.  
(Investment manager for Canara Robeco Mutual Fund)

Date: 29-04-2022  
Place: Mumbai  
Sd/-  
Authorised Signatory

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

**Baroda BNP PARIBAS MUTUAL FUND**

Investment Manager: Baroda BNP Paribas Asset Management India Private Limited (AMC)  
Corporate Identity Number (CIN): U65991MH2003PT142972

Registered Office: Crescenzo, 7<sup>th</sup> Floor, G-Block, Bandra Kurla Complex, Bandra - East, Mumbai - 400 051.  
Website: [www.barodabnpbbasmf.in](http://www.barodabnpbbasmf.in) • Toll Free: 18002670189

**NOTICE CUM ADDENDUM NO. 36/2022**

**Disclosure of Unaudited Half Yearly Financial Results of the Schemes of Baroda BNP Paribas Mutual Fund (the Fund):**

**NOTICE IS HEREBY GIVEN THAT** in terms of Regulation 59 of SEBI (Mutual Funds) Regulations, 1996, the Unaudited Financial Results of the Schemes of Baroda BNP Paribas Mutual Fund for the Half year ended March 31, 2022 has been hosted on the website of the Fund (<https://www.barodabnpbbasmf.in/downloads/scheme-financials>) and AMFI respectively.

For Baroda BNP Paribas Asset Management India Private Limited  
(Formerly BNP Paribas Asset Management India Private Limited)  
(Investment Manager to Baroda BNP Paribas Mutual Fund)

Sd/-  
Authorised Signatory

Date : April 29, 2022  
Place: Mumbai

**MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS,  
READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.**

**Biocon**

EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

Particulars	(Rs. in Million, except per equity share data)		
	3 months ended 31.03.2022 (Audited)	Year ended 31.03.2022 (Audited)	Year ended 31.03.2021 (Audited)
I Total income from operations	24,088	81,840	71,431
II Net profit before tax, exceptional items and non-controlling interest	3,835	10,942	10,551
III Net profit before tax and non-controlling interest	3,425	9,831	10,677
IV Profit after tax and non-controlling interest	2,386	6,484	7,405
V Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	2,980	7,451	8,987
VI Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,000
VII Reserve [Excluding Revaluation Reserve] as shown in the audited balance sheet	-	78,313	70,260
VIII Earnings per share [of Rs. 5 each]	(not annualised)	(annualised)	(annualised)
(a) Basic	2.00	5.44	6.24
(b) Diluted	1.99	5.42	6.19

## 1. Key standalone financial information (Rs. in Million)

Particulars	(Rs. in Million)		
	3 months ended 31.03.2022 (Audited)	Year ended 31.03.2022 (Audited)	Year ended 31.03.2021 (Audited)
I Total income from operations	5,177	17,382	20,284
II Profit before tax	592	1,397	3,588
III Profit after tax	381	861	2,805

2. The audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on April 28, 2022. The reports of the statutory auditors are unqualified.

3. These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

4. The above is an extract of the detailed format of audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.biocon.com](http://www.biocon.com).

## GOKALDAS EXPORTS LIMITED

Corporate Identification Number (CIN): L18101KA2004PLC033475

Regd. Office : No. 25, 2nd Cross, 3rd Main, Industrial Suburb, Yeshwanthpur, Bangalore 560022.

Tel: +91 80 68951000 Fax: +91 80 68951001 E-mail: [info@gokaldasexports.com](mailto:info@gokaldasexports.com) Website: [www.gokaldasexports.com](http://www.gokaldasexports.com)

## Statement of audited Standalone and Consolidated Ind AS Financial Results for the quarter and year ended March 31, 2022

(Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015) (in Rs. lakh, except earnings per share)

Sl. No.	Particulars	Standalone				Consolidated					
		Quarter Ended		Year Ended		Quarter Ended		Year Ended			
		Mar 31, 2022	Dec 31, 2021	Mar 31, 2021	Mar 31, 2022	Mar 31, 2021	Dec 31, 2021	Mar 31, 2021	Mar 31, 2022	Mar 31, 2021	
1	Total Income	58,781.28	52,372.00	37,202.99	1,80,003.49	1,22,140.28	58,795.47	52,406.41	37,267.32	1,80,100.34	1,22,293.69
2	Net profit/(Loss) before tax and exceptional items	5,227.87	3,843.42	1,574.88	11,672.97	2,630.03	5,237.71	3,859.49	1,616.58	11,703.13	2,661.80
3	Net profit/(Loss) before tax and after exceptional items	5,227.87	3,843.42	1,574.88	11,672.97	2,630.03	5,237.71	3,859.49	1,616.58	11,703.13	2,661.80
4	Net Profit/(Loss) after tax and exceptional items	6,076.15	2,995.14	1,569.17	11,672.97	2,624.32	6,090.99	3,011.21	1,603.94	11,708.13	2,649.16
5	Total Comprehensive Income for the period / year	5,301.01	4,389.38	1,340.26	12,381.87	5,796.78	5,313.18	4,406.20	1,372.79	12,416.61	5,821.63
6	Paid-up equity share capital (Face value Rs. 5 each, fully paid up)	2,948.85	2,948.37	2,144.78	2,948.85	2,144.78	2,948.85	2,948.37	2,144.78	2,948.85	2,144.78
7	Other equity as shown in the Audited Balance Sheet of the previous year	-	-	-	68,014.11	27,042.14	-	-	-	67,868.70	26,861.99
8	Earnings Per Equity Share (EPS)										
	Basic :	10.30	5.17	3.66	23.01	6.12	10.33	5.20	3.74	23.08	6.18
	Diluted :	10.00	5.01	3.47	22.07	5.78	10.02	5.04	3.55	22.14	5.83

**Notes :**

1. The figures for quarter ended March 31 of current and the previous years in the standalone and consolidated Ind AS financial results are the balancing figures between the audited figures in respect of the full financial years and the unaudited published year-to-date figures for nine months ended December 31 for respective years.

2. The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the stock exchange websites ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)) and on the company's website ([www.gokaldasexports.com](http://www.gokaldasexports.com)).

For Gokaldas Exports Ltd.  
Sd/-

**Sivaramkrishnan Ganapathi**  
Managing Director  
DIN: 07954560

Place: Bengaluru  
Date: April 29, 2022

## "IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

## HFCL LIMITED

Regd. Office : 8, Electronics Complex, Chambaghat, Solan-173213 (Himachal Pradesh). Tel. : (+91-1792) 230644, Fax No. : (+91-1792) 231902  
E-mail: [secretarial@hfcl.com](mailto:secretarial@hfcl.com) Website: [www.hfcl.com](http://www.hfcl.com) / Corporate Identity Number (CIN): L64200HP1987PLC007466

## STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2022

(Rs. in Crore unless otherwise stated)

Sl. No.	Particulars	Standalone				Consolidated				
		Three months ended		Preceding three months ended		Three months ended		Preceding three months ended		
		March 31, 2022	December 31, 2021	March 31, 2021	March 31, 2022	March 31, 2021	March 31, 2022	December 31, 2021	March 31, 2021	
1.	Total income from operations	1,065.96	1,107.36	1,276.94	4,286.44	4,105.87	1,182.98	1,215.21	1,391.40	4,422.96
2.	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary Items)	83.00	94.79	109.25	381.67	300.00	93.35	115.85	118.24	448.49
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	83.00	94.79	109.25	381.67	295.87	93.35	109.47	118.24	442.11
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	61.94	70.12	82.50	282.78	222.86	68.13	81.10	86.47	325.86
5.	Total comprehensive income for the period (comprising net profit (after tax) and other Comprehensive Income (after tax) for the period)	62.43	71.33	84.14	284.57	227.54	68.65	82.24	88.14	327.57
6.	Equity Share Capital	137.49	137.43	128.44	137.49	128.44	137.49	137.43	128.44	137.49
7.	Other Equity	-	-	-	2,590.87	1,748.05	-	-	2,680.88	1,795.03
8.	Earnings Per Share (Face Value Re. 1/- each) (for continuing and discontinuing operations)									
	Basic (Rs.)	0.45	0.53	0.64	2.15	1.74	0.47	0.59	0.66	2.38
	Diluted (Rs.)	0.45	0.54	0.64	2.15	1.74	0.46	0.60	0.66	2.38

**NOTES:**

1. The above Audited Standalone & Consolidated Financial Results of the Company for the fourth quarter and financial year ended 31st March, 2022 have been reviewed and recommended by the Audit Committee and were approved by the Board of Directors of the Company at their respective meetings held on 29th April, 2022.

2. The above Financial Results are in compliance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.

3. The Board has recommended a Dividend @ 18%, i.e., Re. 0.18 per equity share of face value of Re. 1/- each, for the financial year ended 31st March, 2022, subject to the approval of shareholders at the ensuing Annual General Meeting (AGM) of the Company or other authorities wherever required. The Dividend for the financial year ended 31st March, 2022, if declared at the ensuing AGM, will be paid to the shareholders within 30 days from the date of declaration.

4. The above is an extract of the detailed format of the Audited Standalone & Consolidated Financial Results of the Company for the fourth quarter and financial year ended 31st March, 2022, filed with stock exchanges (NSE & BSE) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Standalone & Consolidated Financial Results of the Company for the fourth quarter and financial year ended 31st March, 2022 are available on the Company's website i.e. [www.hfcl.com](http://www.hfcl.com) and stock exchange website at BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).

5. The figures of the previous periods have been re-grouped/ re-arranged wherever considered necessary.

Place: New Delhi  
Date: 29th April, 2022

By order of the Board  
(Mahendra Nahata)  
Managing Director  
DIN: 00052898

**The Kerala Minerals and Metals Ltd.**  
(A Govt. of Kerala Undertaking)  
Sankaramangalam, Chavara - 691 583  
Kollam, Kerala, India. Phone: 0476-2686722 to 2686733 (12 Lines). E-mail: [contact@kmmml.com](mailto:contact@kmmml.com)

**TENDER NOTICE**

Competitive Tenders are invited for the following. For more details please visit the E-tendering Portal <https://tenders.kerala.gov.in> or [www.kmmml.com](http://www.kmmml.com)

No.	Tender ID	Items
1	2022_KMML_488181_1	For the supply of CS Pipe
2	2022_KMML_487957_1	For the supply of 4100.00 MT of Sodium Silicate
3	2022_KMML_487191_1	For the supply of HT Power Cable

Chavara, 29.04.2022. Sd/-, DGM (Mts). For the Kerala Minerals and Metals Ltd.

**Zydus Wellness**

ZYDUS WELLNESS LIMITED  
A Subsidiary of Zydus Lifesciences Limited  
[CIN:L15201GJ1994PLC023490]

Regd. Office : Zydus Corporate Park, Scheme No. 63, Survey No. 536, Near Vaishodevi Circle, Khoraj (Gandhinagar), Sarthej - Gandhinagar Highway, Ahmedabad - 382481.  
Telephone : +91-079-7180000, +91-079-4804000  
Website : [www.zyduswellness.com](http://www.zyduswellness.com); Email ID : [charraj.dagar@zyduswellness.com](mailto:charraj.dagar@zyduswellness.com)

**NOTICE TO THE SHAREHOLDERS**

For transfer of shares to the Investor Education and Protection Fund ("IEPF")  
NOTICE is hereby given to the shareholders of Zydus Wellness Limited ("the Company") that pursuant to the provisions of section 124(6) of the Companies Act, 2013 ("the Act") and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules"), the Company is required to transfer all such shares in respect of which dividend has remained unpaid / unclaimed by the shareholders for seven consecutive years or more to the IEPF.

The Company has uploaded the details of such shareholders and shares that are due for transfer to IEPF on its website under the Investor Relation section at [www.zyduswellness.com](http://www.zyduswellness.com). Further, the Company has completed the posting of notices to all the concerned shareholders pursuant to section 124(6) of the Act and Rules made thereunder, whose dividend has remained unclaimed for consecutive period of seven years, at their address registered with the Company, providing complete details of the unclaimed dividend, if not claimed then the shares will be transferred to IEPF.

For further details and for making a valid claim, of the unclaimed dividend lying with the Company, the shareholders who have not claimed their dividend for a period of seven consecutive years from the financial year 2014-2015 can write to the Company / Registrar and Transfer Agent on or before July 31, 2022 and sign as per the specimen signature registered with the Company at the registered office address mentioned above or to the Registrar and Transfer Agent at the following address:

Link Intime India Private Limited at 506-508, Amarnath Business Centre-1, Beside Gala Business Centre, Near St. Xavier's College Corner, Off C. G. Road, Navrangpura, Ahmedabad-380006.

Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF pursuant to the said section and Rules. Please also be informed that, upon such transfer, shareholders can claim the transferred shares along with dividends by making an application to the IEPF authority in Web Form IEPF-5 as prescribed under the Rules and the same is available at IEPF website i.e. [www.iepf.gov.in](http://www.iepf.gov.in).

For ZYDUS WELLNESS LIMITED  
Sd/- DHANRAJ P. DAGAR  
COMPANY SECRETARY  
MEMBERSHIP NO. : A33308

Place : Ahmedabad  
Date : April 29, 2022

**zydus**

ZYDUS LIFESCIENCES LIMITED  
(Formerly known as Cadila Healthcare Limited)  
CIN L24230GJ1995PLC025878

Regd. Office : Zydus Corporate Park, Scheme No. 63, Survey No. 536, Near Vaishodevi Circle, Khoraj (Gandhinagar), Sarthej - Gandhinagar Highway, Ahmedabad - 382481.  
Telephone : +91-79-7180000, +91-79-4804000  
Website : [www.zyduslife.com](http://www.zyduslife.com); Email : [dshavalsoni@zyduslife.com](mailto:dshavalsoni@zyduslife.com)

**NOTICE TO THE SHAREHOLDERS**

For transfer of shares to the Investor Education and Protection Fund ("IEPF")  
NOTICE is hereby given to the shareholders of Zydus Lifesciences Limited ("the Company") that pursuant to the provisions of section 124(6) of the Companies Act, 2013 ("the Act") and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the Rules"), the Company is required to transfer all such shares in respect of which dividend has remained unpaid / unclaimed by the shareholders for seven consecutive years or more to the IEPF.

The Company has uploaded the details of such shareholders and shares that are due for transfer to IEPF on its website under the Investor Relation section at [www.zyduslife.com](http://www.zyduslife.com). Further, the Company has completed posting of notices to all the concerned shareholders pursuant to section 124(6) of the Act and Rules made thereunder, whose dividend has remained unclaimed for consecutive period of seven years, at their address registered with the Company, providing complete details of the shares and unclaimed dividend, if not claimed will be transferred to IEPF.

For further details and for making a valid claim, for the unclaimed dividend lying with the Company, the shareholders who have not claimed their dividend for a period of seven consecutive years from the financial year 2014-2015 can write to the Company / Registrar and Transfer Agent on or before August 14, 2022 and sign as per the specimen signature registered with the Company at the registered office address mentioned above or to the Registrar and Transfer Agent at the following address:

Link Intime India Private Limited at 506-508, Amarnath Business Centre-1, Beside Gala Business Centre, Near St. Xavier's College Corner, Off C. G. Road, Navrangpura, Ahmedabad-380006.

Please note that no claim shall lie against the Company in respect of unclaimed dividend amount and shares transferred to IEPF pursuant to the said section and Rules. Please also be informed that, upon such transfer, shareholders can claim the transferred shares along with dividends by making an application to the IEPF authority in Web Form IEPF-5 as prescribed under the Rules and the same is available at IEPF website i.e. [www.iepf.gov.in](http://www.iepf.gov.in).

For ZYDUS LIFESCIENCES LIMITED  
(Formerly known as Cadila Healthcare



**EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022**

(Rs. in Million, except per equity share data)

Particulars	3 months ended 31.03.2022	Year ended 31.03.2022	Year ended 31.03.2021
	(Audited)	(Audited)	(Audited)
I Total income from operations	24,088	81,840	71,431
II Net profit before tax, exceptional items and non-controlling interest	3,835	10,942	10,551
III Net profit before tax and non-controlling interest	3,425	9,831	10,677
IV Profit after tax and non-controlling interest	2,386	6,484	7,405
V Total comprehensive income for the period attributable to shareholders [comprising profit for the period (after tax) and other comprehensive income (after tax)]	2,980	7,451	8,987
VI Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,000
VII Reserve [Excluding Revaluation Reserve] as shown in the audited balance sheet		78,313	70,260
VIII Earnings per share [of Rs. 5 each]	(not annualised)	(annualised)	(annualised)
(a) Basic	2.00	5.44	6.24
(b) Diluted	1.99	5.42	6.19

**1. Key standalone financial information**

(Rs. in Million)

Particulars	3 months ended 31.03.2022	Year ended 31.03.2022	Year ended 31.03.2021
	(Audited)	(Audited)	(Audited)
I Total income from operations	5,177	17,382	20,284
II Profit before tax	592	1,397	3,588
III Profit after tax	381	861	2,805

- The audited standalone and consolidated financial results for the quarter and year ended **March 31, 2022** in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on **April 28, 2022**. The reports of the statutory auditors are unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above is an extract of the detailed format of audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.biocon.com](http://www.biocon.com).